Eli Lilly and Novo Stock Sold Off. Don’t Blame Their Diet Drugs.

Stock in Eli Lilly and Novo Nordisk outperformed last year, largely because of remarkable demand for new drugs that drive weight loss in patients afflicted with diabetes and obesity. Both stocks were ...

Buy Eli Lilly Stock. Its Obesity Drug Mounjaro Will Be a Hit, Analyst Says.

Text size Eli Lily said in August that initial demand for Mounjaro was strong. Daniel Acker/Bloomberg Eli Lilly’s novel treatment for diabetes and obesity could become one of history’s bestselling dru...

UnitedHealth to Drop Copays on Some Widely Used Drugs

UnitedHealth Group Inc. said it would eliminate copayments and other out-of-pocket charges for patients on some widely used drugs in certain plans next year, including insulin and the anti-overdose tr...

The Days of Big Pharma Are Over. Big Biotech Is on Its Way.

W hen GlaxoSmithKline spins off its enormous division selling drugstore staples like Advil and Tums next month, it will represent more than just the latest shuffling of assets among corporate giants. ...